Antibody Maker Loses License Over Animal Welfare Violations

The US Department of Agriculture orders Santa Cruz Biotechnology to pay a $3.5 million fine and to cease selling research antibodies.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

goatsFLICKR, DJANIMALAccording to a settlement with the US Department of Agriculture (USDA) announced late last week (May 20), Santa Cruz Biotechnology will lose its dealer’s license. The company, which has for years been accused of various animal welfare violations, will be able to sell its remaining antibody stocks, but that’s it. The firm must also pay a $3.5 million fine—an order of magnitude greater than any previous fines for violations of the federal Animal Welfare Act, BuzzFeed News reported.

The settlement follows years of allegations of the Santa Cruz Biotech’s mistreatment of the goats and rabbits it used to generate antibodies. In addition to inspectors’ reports of poor animal treatment, one veterinarian testified at a 2015 hearing that the company had a barn of 800 goats that it had kept hidden from inspectors for years.

“The current settlement includes the ‘neither admits nor denies’ language about the company’s culpability, but you don’t give up a big piece of your business and agree to the largest animal-welfare fine in USDA history if you think you have a good case,” Derek Lowe wrote on his blog.

“[The settlement] should serve as a loud and clear message to all research facilities, animal dealers, exhibitors and airlines regulated ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies